These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 31639551)

  • 1. Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti-PD-1 therapy.
    Ikematsu Y; Tanaka K; Yanagihara T; Liu R; Inoue H; Yoneshima Y; Ota K; Iwama E; Takata S; Hata K; Takahata Y; Wataya H; Nakanishi Y; Okamoto I
    Lung Cancer; 2019 Dec; 138():58-64. PubMed ID: 31639551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
    Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.
    Kurozumi S; Fujii T; Matsumoto H; Inoue K; Kurosumi M; Horiguchi J; Kuwano H
    Med Mol Morphol; 2017 Dec; 50(4):185-194. PubMed ID: 28936553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PD-L1/PD-1 pathway promotes dysfunction, but not "exhaustion", in tumor-responding T cells from pleural effusions in lung cancer patients.
    Prado-Garcia H; Romero-Garcia S; Puerto-Aquino A; Rumbo-Nava U
    Cancer Immunol Immunother; 2017 Jun; 66(6):765-776. PubMed ID: 28289860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
    Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
    Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation.
    Reyes RM; Deng Y; Zhang D; Ji N; Mukherjee N; Wheeler K; Gupta HB; Padron AS; Kancharla A; Zhang C; Garcia M; Kornepati AVR; Boyman O; Conejo-Garcia JR; Svatek RS; Curiel TJ
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33849925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
    Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
    J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.
    Kim R; Keam B; Kim S; Kim M; Kim SH; Kim JW; Kim YJ; Kim TM; Jeon YK; Kim DW; Chung DH; Lee JS; Heo DS
    BMC Cancer; 2019 Jan; 19(1):19. PubMed ID: 30616523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity.
    Tanegashima T; Togashi Y; Azuma K; Kawahara A; Ideguchi K; Sugiyama D; Kinoshita F; Akiba J; Kashiwagi E; Takeuchi A; Irie T; Tatsugami K; Hoshino T; Eto M; Nishikawa H
    Clin Cancer Res; 2019 Aug; 25(15):4808-4819. PubMed ID: 31076547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of immune-checkpoint inhibitors in lung cancer.
    Jain P; Jain C; Velcheti V
    Ther Adv Respir Dis; 2018; 12():1753465817750075. PubMed ID: 29385894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
    Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
    J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.
    Araujo B de Lima V; Borch A; Hansen M; Draghi A; Spanggaard I; Rohrberg K; Reker Hadrup S; Lassen U; Svane IM
    Cytotherapy; 2020 Apr; 22(4):204-213. PubMed ID: 32201034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in the clinical development of immune checkpoint blockade therapy.
    Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
    Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade.
    Biton J; Ouakrim H; Dechartres A; Alifano M; Mansuet-Lupo A; Si H; Halpin R; Creasy T; Bantsimba-Malanda C; Arrondeau J; Goldwasser F; Boudou-Rouquette P; Fournel L; Roche N; Burgel PR; Goc J; Devi-Marulkar P; Germain C; Dieu-Nosjean MC; Cremer I; Herbst R; Damotte D
    Am J Respir Crit Care Med; 2018 Oct; 198(7):928-940. PubMed ID: 29518341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors.
    Chee J; Watson MW; Chopra A; Nguyen B; Cook AM; Creaney J; Lesterhuis WJ; Robinson BW; Lee YCG; Nowak AK; Lake RA; McDonnell AM
    BMC Res Notes; 2018 Dec; 11(1):864. PubMed ID: 30518402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased CD3+ T cells with a low FOXP3+/CD8+ T cell ratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patients.
    Kim H; Kwon HJ; Han YB; Park SY; Kim ES; Kim SH; Kim YJ; Lee JS; Chung JH
    Mod Pathol; 2019 Mar; 32(3):367-375. PubMed ID: 30297881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine and checkpoint blockade exhibit synergistic anti-tumor effects in a model of murine lung carcinoma.
    Du B; Wen X; Wang Y; Lin M; Lai J
    Int Immunopharmacol; 2020 Sep; 86():106694. PubMed ID: 32570034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis.
    Ajona D; Ortiz-Espinosa S; Moreno H; Lozano T; Pajares MJ; Agorreta J; Bértolo C; Lasarte JJ; Vicent S; Hoehlig K; Vater A; Lecanda F; Montuenga LM; Pio R
    Cancer Discov; 2017 Jul; 7(7):694-703. PubMed ID: 28288993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.